Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

@article{Sandborn2012TofacitinibAO,
  title={Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.},
  author={W. Sandborn and S. Ghosh and J. Pan{\'e}s and I. Vrani{\'c} and C. Su and Samantha Rousell and W. Niezychowski},
  journal={The New England journal of medicine},
  year={2012},
  volume={367 7},
  pages={
          616-24
        }
}
BACKGROUND Ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally effective. One additional treatment may be tofacitinib (CP-690,550), an oral inhibitor of Janus kinases 1, 2, and 3 with in vitro functional specificity for kinases 1 and 3 over kinase 2, which is expected to block signaling involving gamma chain-containing cytokines including interleukins 2, 4, 7, 9, 15, and 21. These cytokines are integral to lymphocyte activation… Expand
542 Citations

Paper Mentions

Interventional Clinical Trial
The hypothesis of the study is that at least one dose of CP 690 550 is superior to placebo (inactive drug) in inducing remission in patients with moderate to severe ulcerative colitis… Expand
ConditionsUlcerative Colitis
InterventionDrug, Other
A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease.
  • 204
TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES.
  • 1
  • PDF
Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data
  • 7
  • PDF
Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes
  • 70
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
  • 652
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
  • 670
  • PDF
The specificity of JAK3 kinase inhibitors.
  • 89
  • Highly Influential
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
  • 424
  • PDF
...
1
2
3
...